CCR
-
BX471 hydrochloride
Catalog No. A21886 non-peptide CCR1 antagonistBX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist with Ki of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. Learn More -
Vercirnon
Catalog No. A21315 CCR9 antagonistVercirnon (GSK-1605786) is an orally bioavailable, selective, and potent antagonist of CCR9, with an IC50 of 10 nM, used in the research of inflammatory bowel diseases. Learn More -
RS102895 hydrochloride
Catalog No. A20918 CCR2 antagonistRS102895 hydrochloride is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1. Learn More -
PF-4136309
Catalog No. A15127 CCR2 antagonistPF-4136309 is a potent, selective, and orally bioavailable CCR2 antagonist, with IC50s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2. Learn More -
GSK2239633A
Catalog No. A12175 CCR4 antagonistGSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96±0.11. Learn More -
Teijin compound 1
Catalog No. A13380 CCR 2 antagonistTeijin compound 1 is a specific CCR 2 antagonist with IC50s of 24 and 180 nM in chemotaxis and binding assay, respectively. Learn More -
Cenicriviroc Mesylate
Catalog No. A17028 CCR2/5 receptors inhibitorCenicriviroc, also known as TAK-652 and TBR-652, is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. Learn More -
CCR4 antagonist 2
Catalog No. A18471 CCR4 antagonistCCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. Learn More -
ML604086
Catalog No. A18969 CCR8 inhibitorML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations. Learn More -
AZ084
Catalog No. A19143 CCR8 antagonistAZ084 is a potent, selective, allosteric and oral active CCR8 antagonist, with a Ki of 0.9 nM. Has potential to treat asthma. Learn More -
GW 766994
Catalog No. A20039 CCR3 antagonistGW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis. Learn More -
INCB3344
Catalog No. A11465 CCR2 antagonistINCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity. Learn More -
LMD-009
Catalog No. A18643 CCR8 agonistLMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM. Learn More -
PF-04634817
Catalog No. A18659 CCR2 /CCR5 dual antagonistPF-04634817 is an orally administered CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. Learn More -
BI-639667
Catalog No. A18747 Human CCR1 antagonistBI-639667 is a potent and selective antagonist of human CCR1. Learn More -
Maraviroc (UK-427857)
Catalog No. A10556 CCR antagonistMaraviroc is an antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. Learn More -
BMS-813160
Catalog No. A17040 CCR2/CCR5 antagonistBMS-813160 is a potent and selective CCR2/CCR5 antagonist with potential immunomodulating and antineoplastic activities. Learn More -
ZK-756326 dihydrochloride
Catalog No. A16363 CCR8 agonistZK-756326 is a potent, selective and non-peptide CCR8 chemokine receptor agonist. ZK 756326 inhibited the binding of the CCR8 ligand I-309 (CCL1), with an IC(50) value of 1.8 μM. Learn More -
NSC5844
Catalog No. A15924 CCR1 agonistNSC5844 is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties. Learn More -
Vicriviroc maleate
Catalog No. A15276 CCR5 antagonistVicriviroc maleate is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1. Learn More -
RS 504393
Catalog No. A15227 CCR2 antagonist.RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 uM for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Learn More -
Aplaviroc
Catalog No. A13471 CCR5 entry inhibitorAplaviroc is a CCR5 entry inhibitor developed for the treatment of HIV infection. Learn More -
Cenicriviroc
Catalog No. A13643 CCR2/CCR5 inhibitorCenicriviroc is an experimental drug candidate for the treatment of HIV infection.Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. Learn More -
TAK-779
Catalog No. A13846 CCR5 antagonistTAK-779 is a novel, potent and selective small-molecule antagonists of CCR5 with the IC50 value of 1.4nM in binding assay. Learn More -
BX471
Catalog No. A14409 CCR1 antagonistBX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1), exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. Learn More -
MK-0812
Catalog No. A11127 CCR2 antagonistMK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models. Learn More -
INCB 3284 dimesylate
Catalog No. A11104 HCCR2 antagonistINCB 3284 dimesylate is a potent, selective hCCR2 antagonist that exhibits potenct antagonism against monocyte chemoattractant molecule binding to hCCR2 and chemotaxis activity. Learn More -
INCB8761 (PF-4136309)
Catalog No. A11136 CCR2 AntagonistINCB8761(PF-4136309) is a potent, selective, and orally bioavailable CCR2 antagonist. Learn More -
Vicriviroc Malate
Catalog No. A10971 CCR5 antagonistVicriviroc Malate is a second generation orally active CCR5 antagonist, which is also a potent inhibitor of HIV-1 entry into target cells, with a mean IC50 =0.46 nM and IC50 =1~10 nM to HIV isolates (n=52). Learn More